NMS Capital has exited its investment in Flourish Research, a US-based clinical trial organization, through a sale to Genstar Capital. No financial terms were disclosed.

Original research ranges from new concepts in human biology and disease pathogenesis to new therapeutic modalities and drug development, to all phases of clinical work, as well as innovative ...

Just one year after introducing the world’s first burn nursing specialty certification, the Board of Certification for Emergency Nursing (BCEN) proudly reports that nearly 500 nurses in both civilian ...

Three distinguished faculty members across the Purdue University system have been elected as 2024 American Physical Society (APS) Fellows, a prestigious recognition given to scientists who have made ...

In a report released on November 6, Brian Skorney from Robert W. Baird maintained a Hold rating on Arbutus Biopharma (ABUS – Research ...

Lonza’s innovative continuous flow technology and mini-monoplant approach are transforming early-phase drug development. How ...

TD Cowen analyst Tyler Van Buren maintained a Buy rating on EyePoint Pharmaceuticals (EYPT – Research Report ... based on EyePoint Pharmaceuticals’ notable advancements in their clinical trials and ...

The project includes the establishment of a Research and Innovation Centre. Construction has commenced on the redevelopment ...

Hoa Lac Stem Cell JSC (HSC) held a groundbreaking ceremony for the HSC Stem Cell Technology Platform (HOSTEP) at Hoa Lac ...

Members of Medigene management as expert speakers, Prof. Dolores Schendel, Chief Scientific Officer and Kirsty Crame, MD, Vice President, Clinical Strategy & DevelopmentPresentations and seminars ...

Parkinson's disease (PD) and Alzheimer's disease (AD) are examples of brain illnesses that begin to develop in patients far ...

Serigen Mediproducts has developed products that can be used to fill cavities in bone or bandage non-healing wounds ...